News | July 18, 2021
Veeda Clinical Research acquires majority stake in Bioneeds
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The company has reported total income of Rs.355.43 crores during FY 2020-21
Subscribe To Our Newsletter & Stay Updated
